Purpose of review An analysis of the technological implementation of extracorporeal CO 2 removal (ECCO 2 R) techniques and of its clinical application. A new classification of ECCO 2 R, based on technological aspects, clinical properties and physiological performance, is proposed.
INTRODUCTION
Mechanical ventilation is the main form of life support for patients with acute respiratory failure and can resolve the impairment of gas exchange alteration in the vast majority of patients with acute respiratory failure [1] . However, evidence has progressively emerged suggesting that mechanical ventilation, although indispensable for survival, may worsen the injured lung and may increase the mortality rate if inappropriately administered [2, 3] . This is particularly true for acute respiratory distress syndrome (ARDS), in which several studies demonstrated that the main reason for high mortality (30-50%) is not severe hypoxemia but rather multiorgan failure (kidneys, heart, liver, etc.), potentially caused by the translocation of various mediators from the lungs through the systemic circulation to peripheral organs and/or augmented by artificial ventilation (ventilatorinduced lung injury, VILI).
The randomized trial carried out by the National Institutes of Health demonstrated that ventilating patients with a tidal volume (V T ) of 6 ml/kg (calculated from predicted body weight, PBW) and with a maximum end-inspiratory plateau pressure (PPLAT) of 30 cm H 2 O instead of ventilating patients with a V T of 12 ml/kg PBW decreased mortality from 39.8 to 31% [4] . However, observational studies carried out in Europe and in the USA demonstrated that there was poor compliance by clinicians in reducing the ventilation volumes and pressures in order to minimize iatrogenic damage caused by mechanical ventilation. A major reason for the underuse of protective ventilatory strategies is the hypercapnia caused by the reduction in ventilatory volumes. Furthermore, recent studies have shown that lung hyperinflation still occurs in approximately 30% of ARDS patients, even though they are being ventilated 'correctly' using the ARDSNet strategy [5] . These studies also suggested that some patients may benefit from a further reduction of V T even when PPLAT is less than 30 cm H 2 O [5, 6] . Bellani et al. [7 && ] recently assessed the intensity of pulmonary inflammation during mechanical ventilation using positron-emission tomography (PET) imaging of (18F) fluoro-2-deoxy-D-glucose to detect the presence of metabolically active inflammatory cells. They showed that PPLAT is significantly correlated with metabolic activity and the correlation increases steeply above 26-27 cm H 2 O, thus suggesting that further limitation of ventilation to values of PPLAT of 25 cm H 2 O or lower may be associated with lower degree of pulmonary inflammation because of less VILI [7 && ]. The idea of partial support (removing only carbon dioxide, with little to no impact on oxygenation: partial extracorporeal support) was proposed in 1977 by Kolobow et al. [8, 9] and Gattinoni et al. [10] . These authors suggested that applying only a few ventilator breaths at low volumes and low peak inspiratory pressures ('lung rest') could prevent damage to the compromised lungs. To reduce complexity, expenses, and side-effects of extracorporeal lung assistance, Pesenti et al. [11] modified an extracorporeal circuit designed for renal replacement therapy by adding to the circuit an oxygenator and proposed the concept of removing 'only a portion of carbon dioxide production' to allow less traumatic ventilator settings. This hypothesis was developed taking into consideration the original observation of Sherlock et al. [12] who found that patients treated with hemodialysis experienced a transient hypocapnia, hypoventilation, and hypoxemia because of the capacity of the hemofilter to remove a significant amount of CO 2 . What Kolobow, Gattinoni, and Pesenti, therefore, proposed may be interpreted nowadays as the optimal protective ventilatory strategy that, 'disconnecting' oxygenation (provided using the 'residual' functional lungs using PEEP and high FiO 2 ) from CO 2 clearance (performed used extracorporeal circuit and membrane lungs), may minimize or prevent VILI.
CARBON DIOXIDE REMOVAL: PHYSIOLOGY AND TECHNIQUES
The use of extracorporeal circuits to support respiratory functions may be described using a 'continuous model' that analyzes and integrates the technological aspects (type of pump, characteristics of the oxygenator, and type and size of catheter), the clinical properties (kind of surgical approach), and the physiological performance (amount of oxygen transferred to the patient and amount of carbon dioxide removed from the patient) [13] (Table 1) .
The lowest complexity level is represented by renal support that requires very low blood flows, which is less invasive for the patients requiring low primer volumes and a small coaxial catheter. With this technique, carbon dioxide is extracted, although at very low levels [12, 14] .
At the other extreme of the complexity scale, total extracorporeal support (ECMO) is able to completely supply the physiological blood gas exchanges, normally performed by the native lungs, and is therefore capable of delivering oxygen and of removing CO 2 equal to the entire metabolic needs of the patient. It is an invasive and complex system, which needs high blood flows (equivalent to the entire cardiac output) and high diameter cannulation. It is also necessary to use high heparin dosage and elevated volume of priming. This device can be connected to patient with a venous-arterial (V-A) setting, therefore in parallel with the pulmonary circulation, also able to support the cardiac function, or in a venous-venous (V-V) setting, sequentially to the pulmonary circulation, preferred in case of respiratory failure alone.
Partial extracorporeal support (ECCO 2 R) represents the intermediate level of technical complexity. V-V ECCO 2 R needs a 14-Fr coaxial catheter to allow a blood flow of 0.3-0.5 l/min, which is constantly guaranteed by a roller nonocclusive pump designed to minimize hemolysis; blood is driven through an oxygenator membrane, which is connected to an oxygen source of 6-8 l/min. Some devices also include a hemofilter in series with the oxygenator
KEY POINTS
From renal to pulmonary dialysis, new techniques rise to assist clinicians in the management of critical patients with organ failures.
Coupling mild extracorporeal support devices with ultraprotective ventilation represents the most promising possibility to obtain the best therapeutic goals in the severe ARDS patients' treatment.
New strategies for ventilation support are currently under investigation, specifically for the treatment of COPD exacerbations and as a bridge for lung transplant.
to allow the extraction of plasmatic water which is then reinfused in the circuit in order to lower hematocrit and prevent blood clotting [15,16 && ]. A centrifugal pump, which creates a radial flow going through an annular fiber oxygenator, has also been used in other veno-venous ECCO 2 R systems. This design maximizes the exchange surface, and, therefore, the device efficiency [15] . Both technological implementations are able to remove up to 25% of carbon dioxide production and can transfer no more than 10 ml/min of oxygen. Low doses of heparin (4-18 IU/min) are necessary to avoid clotting occurrence [15,16 && ,17] .
CLINICAL USE OF EXTRACORPOREAL CARBON DIOXIDE REMOVAL
A brief overview of past years' studies exploring ECCO 2 R techniques' safety and feasibility is shown in Table 2 .
Acute respiratory distress syndrome
Gattinoni et al. [18] reported the first systematically collected clinical experience of the use of ECCO 2 R in patients with severe ARDS. Mechanical ventilation was limited to apneic oxygenation and to 3-5 sighs every minute with a peak inspiratory pressure less than 35-45 cm H 2 O; PEEP ranged between 15 and 25 cm H 2 O. Carbon dioxide removal was performed using a pump-driven veno-venous bypass allowing blood flow to pass through double-membrane lungs (9 m 2 total membrane surface area). Extracorporeal blood flow was progressively increased from 200 to 300 ml/min to the selected maintenance flow (20-30% of cardiac output). Although the observed mortality rate was lower than expected, there was no concurrent randomized control group; as well, several episodes of severe bleeding were reported. In 1993, Brunet et al. [19] achieved a mortality rate of 50% in ARDS patients, utilizing a V-V ECCO 2 R coupled with protective ventilation that reached a maximum tidal volume of 325 ml. They also reported a 21% of hemorrhagic events and an 8% of peripheral vascular problems. One year later, Morris et al. [20] presented the results of a randomized controlled trial that investigated the use of pressure-controlled inverse-ratio ventilation vs. ECCO 2 R techniques associated to mechanical ventilation in ARDS patients. The trial, showing no significant difference in survival (38%) between the two groups, also highlighted numerous episodes of severe bleeding and the need of major anticoagulation with consequent hemorrhagic complications.
In 2006, Bein et al. [21] published a retrospective experience with an arteriovenous pumpless device with an interposed membrane oxygenator sustained by patients' hemodynamic status. This artificial lung was able to remove up to 50% of the total body CO 2 production, with a blood flow of around 1-2 l/min. The authors reported the occurrence of serious complications in 24.4% of patients with also episodes of ischemia of lower limbs after arterial cannulation.
Under these circumstances, the clinical and technological implementation of ECCO 2 R implemented until a few years ago is closer to full extracorporeal support, than to that envisioned in the 'simple' devices as described in Table 1 . The more invasive and complex systems are characterized by flow equal to or higher than 1000 ml, wide bore catheters, high doses of heparin, large volumes of blood to 'prime' the circuit, and numerous blood transfusions because of loss in the circuitry and from the accesses. The rates of major complications reported in clinical studies using ECCO 2 R are Table 3 . These data help explain why ECCO 2 R has been limited to the sickest patients in whom all other treatments have failed [22] and to centers with large expertise [23, 24] . In 2009, Terragni et al. [5] presented a ventilation model of very low V T (4 ml/kg of PBW) for severe ARDS patients who, despite a ventilation setting derived from the ARDSNet Trial [4] , showed morphological evidence of tidal hyperinflation. This ventilatory model, that was proven to be able to decrease inflammatory markers associated with VILI, was coupled with a V-V ECCO 2 R device, which allowed safe and efficient management of acidosis resulting from V T reduction [16 && ]. The device used in Terragni's study represents a modification of renal replacement therapy circuits and is characterized by veno-venous bypass systems, extracorporeal blood flow of 0.3-0.5 l/min; smaller bore catheters or a single co-axial catheter similar to those currently used for renal ultrafiltration procedures; very low doses or no heparin; and minimal volumes for 'priming'. This technological implementation of LFPPV-ECCO 2 R is therefore closer to devices for renal replacement therapy than full ECMO (Table 1) and may explain the lack of significant side-effects during the use of low-flow CO 2 removal bypass (Table 3) .
Chronic obstructive pulmonary disease ECCO 2 R techniques could also represent a revolutionary tool for the approach of other clinical situations like chronic obstructive pulmonary disease (COPD) exacerbations treatment in patients at risk of noninvasive ventilation failure or intracranial bleeding management when associated to severe ARDS. Garcia et al. [25 && ] recently presented preliminary data on the attempt to optimize ECMO in patients with COPD to reduce ventilatory support. The study reports 10 patients (mean age of 45 AE 14 years) treated with ECMO during weaning from all respiratory support or as a bridge to lung transplant. The mean duration of ECMO was 20 (9-59) days, with average mean blood flows of 3.5 l/min (1.6-4.9), and levels of CO 2 removal and O 2 transfer of 228 ml/min (54-570) and 127 ml/min (36-529), respectively. Six of ten patients were weaned from respiratory support or underwent transplantation and survived to discharge from the hospital. The remaining four patients died of sepsis and withdrawal of care.
Bridge to lung transplant ECCO 2 R devices with pump support have been developed as bridges to lung transplant in patients with severe, unresponsive respiratory failure. In a recent report, ECCO 2 R low-flow devices have been proved as simple and efficient methods to support patients with mild hypoxia and severe hypercapnia refractory to mechanical ventilation [26 && ]. Ruberto et al. [27] reported also the experience of venovenous extracorporeal support in primary graft dysfunction after single-lung transplant with a control of respiratory acidosis, decrease of PaCO 2 , and reduction of ventilatory support.
CONCLUSION
Technological improvement has permitted the creation of new devices that are able to perform ECCO 2 R at lower blood flows with less invasiveness. However, our knowledge is limited to case reports and case series studies. Future randomized clinical trials that will soon be initiated will help physicians to consider minimally invasive ECCO 2 R devices, coupled with mechanical ventilation setting, as an alternative to mechanical ventilation alone to prevent and minimize the side-effects of ventilatory support.
